Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic oncology products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

Telix reports 53% year-over-year revenue growth and raises full-year guidance.Unaudited group revenue for the quarter en...
14/10/2025

Telix reports 53% year-over-year revenue growth and raises full-year guidance.

Unaudited group revenue for the quarter ended 30 September 2025 was approximately US$206 million. Full-year 2025 revenue guidance has been increased to US$800–820 million.

Telix’s therapeutics and precision medicine programs made significant progress this quarter, with Part 2 of the ProstACT Global trial now open and first patients dosed in the Phase 3 BiPASS trial.

With CMS reimbursement now effective for Gozellix®, a growing customer base and the continued European expansion of Illuccix®, Telix enters Q4 in a strong position.

Read the full announcement here: https://bit.ly/4q8SjaV

And the winner of the 2025 EANM Sanjiv Sam Gambhir Award is… Dan Cohen from the Weizmann Institute of Science!Congratula...
08/10/2025

And the winner of the 2025 EANM Sanjiv Sam Gambhir Award is… Dan Cohen from the Weizmann Institute of Science!

Congratulations Dan on your achievement, and best of luck for your visitorship at Stanford University.

A big thank you to the European Association of Nuclear Medicine (EANM) for the opportunity to support the next generation of scientists and physicians through this exciting award, in memory of a pioneer in nuclear medicine and molecular imaging.

Thank you to the brilliant hosts, Joshua James M. & Sophie Veldhuijzen van Zanten and jury members, Burger Irene, Desiree Deandreis, Stefano Fanti & Andrei Iagaru.

06/10/2025

Nuclear medicine is transforming cancer care.

During , we’re highlighting how Telix is advancing the field by developing diagnostic imaging and targeted therapies that work together to better see and treat cancer.

Our theranostic pipeline is among the most advanced in the industry, focused on areas of critical unmet medical need in urologic oncology, neuro-oncology, hematology and other solid tumors.

🎥 Watch this short video to discover how Telix’s pipeline is advancing innovative treatment options for patients.

Do you want to shape the future of nuclear medicine? Explore career opportunities with Telix: https://telixpharma.com/careers/

Telix’s Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400 (177Lu-DOTAGA.Glu.(FAPi)₂), has been pub...
06/10/2025

Telix’s Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400 (177Lu-DOTAGA.Glu.(FAPi)₂), has been published in the Journal of Nuclear Medicine.

In a retrospective analysis, Dr. Sanjana Ballal and colleagues from AIIMS, New Delhi, report that TLX400 demonstrated clinical antitumor activity with a manageable safety profile in patients with advanced sarcoma — a population with limited treatment options.

The publication provides further validation of the clinical and development potential of Telix’s FAP platform across solid tumors, including aggressive cancers such as sarcoma.

Read the full publication in the Journal of Nuclear Medicine: https://jnm.snmjournals.org/content/early/2025/08/21/jnumed.125.270186

Read more on our website here: https://telixpharma.com/news-views/tlx400-therapy-published-in-journal-of-nuclear-medicine/

TLX400 has not received a marketing authorization in any jurisdiction

Join Telix at EANM in Barcelona this Sunday for our sponsored symposium, “From pan-tumor innovation to theranostic preci...
05/10/2025

Join Telix at EANM in Barcelona this Sunday for our sponsored symposium, “From pan-tumor innovation to theranostic precision: Fibroblast activation protein (FAP) and carbonic anhydrase IX (CAIX) case studies.”

The event will be chaired by Prof. Antoine Italiano, with internationally recognised experts sharing perspectives on the clinical potential of FAP and CAIX in radiomolecular oncology.

Don’t miss this fascinating discussion.

More information on the symposium can be found here: https://telixpharma.com/telix-at-eanm-2025/

Telix is set for a record-breaking presence at the 38th Annual Congress of the European Association of Nuclear Medicine ...
01/10/2025

Telix is set for a record-breaking presence at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) – the world’s largest gathering of nuclear medicine professionals.

This year, 28 Telix-related abstracts will be presented, highlighting progress across our late-stage and next-generation clinical programs, MedTech, and R&D.

Key highlights include:

🔵 Phase 3 ProstACT Global therapy trial (TLX591) in prostate cancer
🔵 IPAX-Linz and IPAX-2 therapy trials (TLX101) in glioma
🔵 Real-world experience with TLX250-CDx in kidney cancer
🔵 Pan-tumor programs targeting FAP

We are also pleased to host a sponsored symposium on CAIX and FAP targeting theranostics, bringing together a distinguished panel of global thought leaders.

We look forward to connecting with you at Booth #78 in Barcelona.

Read more on our website here: https://telixpharma.com/telix-at-eanm-2025/

TLX591, TLX101 and TLX250-CDx have not received a marketing authorization in any jurisdiction.

25/09/2025

Even as a physician, hearing the word ‘cancer’ filled Dr. Keith Crawford with fear.

After losing his father to the disease and later facing his own diagnosis, he understood how devastating prostate cancer can feel.

Now, as Director of Clinical Trials and Education at the Prostate Health Education Network, Dr. Crawford works every day to give hope to patients and their families, showing that prostate cancer is not the end, particularly if it is caught early.

This Prostate Cancer Awareness Month, Telix is sitting down with patients, advocates, and physicians to highlight unmet needs and how innovation is transforming prostate cancer care.

To learn more about how Telix is harnessing the theranostic approach to transform prostate cancer care visit: telixpharma.com/prostate

The U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through payment status for Gozelli...
23/09/2025

The U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through payment status for Gozellix® (kit for gallium-68 gozetotide injection), Telix’s next-generation PSMA-PET imaging agent for suspected metastatic or recurrent prostate cancer.

Effective 1 October 2025, this designation enables separate reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS).

This will reduce the out-of-pocket burden for patients, enhance patient access to advanced prostate cancer imaging and simplify payment for providers.

Read more on our website here: https://bit.ly/4mzaVOD

Selected Important Safety Information:

● There is a risk PET scan images with GOZELLIX may be misinterpreted or may be affected by other factors.

● GOZELLIX involves exposure to small amounts of radioactivity; long-term cumulative radiation exposure is associated with increased cancer risk.

● GOZELLIX is used with an Ascorbic Acid Stabilizer, which contains sodium metabisulfite, a sulfite that may cause life-threatening hypersensitivity reactions including anaphylaxis.

● The most commonly reported adverse reactions include fatigue, nausea, constipation and vomiting. These adverse reactions each typically occurred in ≤1.2% of patients in clinical trials.

This is not the full important safety information. The approved uses and additional safety information is available at www.GOZELLIX.com/ -information.

23/09/2025

Radio-guided surgery can only make a difference if surgeons have the training to do it confidently.

That’s why Telix is collaborating with IMRA Surgical to create the first hydrogel surgical model that simulates radiation detection, supporting training in radio-guided surgery with our SENSEI® drop-in gamma probe.

Building on IMRA’s expertise in surgical models, the collaboration will deliver a realistic hands-on experience for surgeons, enabling them to adopt this advanced radio-guided technology more quickly.

Learn more on our website here: https://bit.ly/4nIgn2p

This Prostate Cancer Awareness Month we’re shining a spotlight on a disease that affects at least 1 in 8 men during thei...
19/09/2025

This Prostate Cancer Awareness Month we’re shining a spotlight on a disease that affects at least 1 in 8 men during their lifetime.

Prostate cancer is the most common cancer in men, yet many are still diagnosed too late and face limited treatment options once it has spread.

Advances in diagnostics and novel therapies are starting to change this outlook, but more progress is needed.

At Telix we’re harnessing the theranostic approach to transform prostate cancer care.
We’re advancing a portfolio of imaging and therapeutic candidates to support earlier and more accurate detection and provide more targeted treatment options.

To learn more about our focus visit: telixpharma.com/prostate

Telix is pleased to support this year’s Prostate Cancer Foundation of Australia Dollar Match Day 💙Every gift to The Long...
17/09/2025

Telix is pleased to support this year’s Prostate Cancer Foundation of Australia Dollar Match Day 💙

Every gift to The Long Run will be matched dollar for dollar by Telix, fuelling life-changing research and support services for men with prostate cancer.

Make your donation go twice as far, and help save lives and improve outcomes for thousands of Australian men.

👉 Give today at thelongrun.org.au

09/09/2025

The first patient has been dosed in Telix’s Phase 3 clinical trial aimed at expanding the indications for its PSMA-PET imaging agents to include prostate cancer diagnosis.

BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study) will evaluate the performance of Illuccix® and Gozellix® in combination with MRI to improve diagnostic accuracy while reducing the need for invasive biopsies.

The aim of the study is to demonstrate that some patients can be effectively stratified to either avoid a biopsy altogether or undergo a single PSMA-PET guided biopsy instead.

Learn more on our website here: https://bit.ly/4gkPuzd

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Telix Pharmaceuticals Limited:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Telix Pharmaceuticals Limited was established in January 2017. We are a clinical-stage biotechnology company developing a pipeline of molecularly-targeted radiation (MTR) therapies to image and treat cancer. Our team is an experienced group of biopharma clinicians and executives, with a passion for radiation biology and oncology.

In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anmi.be.

Our products currently focus on unmet needs in cancer care, specifically in:


  • Prostate